Novartis Ag (NVS) Long-Term Deferred Tax (2009 - 2026)

Novartis Ag has disclosed Long-Term Deferred Tax across 18 years of filings, most recently posting $5.3 billion for Q2 2026.

• In Q2 2026, Long-Term Deferred Tax rose 1.44% year-over-year to $5.3 billion; the TTM figure through Jun 2026 stood at $5.3 billion (up 1.44% YoY), while the FY2025 annual figure was $5.4 billion, up 24.75% from the prior year.
• Long-Term Deferred Tax came in at $5.3 billion for Q2 2026 at Novartis Ag, up from $5.2 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $5.6 billion in Q3 2025 to a low of $51.0 million in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $4.2 billion, with a median of $4.3 billion recorded in 2023.
• Year-over-year, Long-Term Deferred Tax tumbled 55.09% in 2022 and jumped 7901.96% in 2023.
• Over 5 years, Long-Term Deferred Tax stood at $3.7 billion in 2022, then increased by 15.24% to $4.3 billion in 2023, then climbed by 1.16% to $4.4 billion in 2024, then climbed by 24.75% to $5.4 billion in 2025, then slipped by 2.96% to $5.3 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $5.3 billion in Q2 2026, $5.2 billion in Q1 2026, and $5.4 billion in Q4 2025.